Roche to present latest oncology advances during ESMO 2014 Congress
Presentations will include
- Results from the Phase III coBRIM study of Roche’s investigational MEK inhibitor cobimetinib plus Zelboraf compared to Zelboraf alone, potentially paving the way for a new standard of care
- Final survival data from the Phase III CLEOPATRA study of the combination of Perjeta, Herceptin and chemotherapy, further confirming the potential of this regimen for people with HER2-positive metastatic breast cancer
- Efficacy data from two Phase III studies of Avastin in HER2-negative, locally recurrent or metastatic breast cancer
- Phase I data from the investigational immunotherapy MPDL3280A in multiple cancer types
Basel, 17 September 2014 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that important new data from its established and pipeline medicine portfolio will be presented during the European Society for Medical Oncology (ESMO) 2014 Congress from 26-30 September in Madrid, Spain. More than 160 abstracts related to Roche medicines across 15 cancer types have been accepted for presentation during the congress. These presentations include one late-breaking abstract as well as 27 oral presentations, two of which are featured in the congress Presidential Symposia.
“The data that will be presented at this year’s meeting show that cancer therapies can have even greater impact for patients when we understand which people will benefit the most from our medicines,” said Sandra Horning, Chief Medical Officer and Head, Global Product Development. “Data from many of Roche’s targeted medicines and combination approaches are being featured at ESMO this year, delivering insights about what may soon be possible for patients.”
Further information about Roche’s contribution to the ESMO 2014 scientific program and wider progress in cancer care will be made available during a Roche Media Briefing from 15:30 – 17:00 CEST on Friday 26th September at the Hotel Meliá Castilla, Madrid. Please note that this event is independently organised by Roche and is not sponsored by ESMO. To register please use the following link: http://roche.cvent.com/MediaBriefing2014.
Follow Roche on Twitter via @roche and keep up to date with ESMO 2014 Congress news and updates by using the hashtag #ESMO14.
|Medicine||Description of study||Abstract number|
|Avastin (bevacizumab) + Xeloda (capecitabine)||Efficacy and safety of maintenance bevacizumab (BEV) with or without capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast cancer (mBC): IMELDA randomised phase III trialEfficacy and safety in TANIA, a randomised phase III trial of continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)||#352O
Sunday 28 September, 14:10#353O
Sunday 28 September, 14:10
|Perjeta (pertuzumab) + Herceptin (trastuzumab)||Final overall survival (OS) analysis from the CLEOPATRA study of first-line (1L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC)||#350O_PR
Presidential Symposium 1, Sunday 28 September, 16:00
|Cobimetinib (investigational MEK inhibitor) + Zelboraf (vemurafenib)||Phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)||#LBA5_PR
Presidential Symposium 2, Monday 29 September, 16:00
|MPDL3280A (investigational anti-PDL1)||Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or chemotherapy (chemo) in patients (pts) with locally advanced or metastatic solid tumoursInhibition of PD-L1 by MPDL3280A leads to clinical activity in pts with metastatic urothelial bladder cancer (UBC)
Immune correlates and long term follow up of a Phase Ia study of MPDL3280A, an engineered [anti]PD-L1 antibody, in patients with metastatic renal cell carcinoma (mRCC)
Saturday 27 September, 11:00#808O
Monday 29 September, 11:00#809O
Monday 29 September, 11:00
About Roche in Oncology
Roche has been working to transform cancer care for more than 50 years, bringing the first specifically designed anti-cancer chemotherapy drug, 5-Flourouracil (5-FU) to patients in 1962. Roche’s commitment to developing innovative medicines and diagnostics for cancers remains steadfast.
The Roche Group’s portfolio of innovative cancer medicines includes: Avastin (bevacizumab); Erivedge (vismodegib); Gazyva/Gazvyaro (obinutuzumab); Herceptin (trastuzumab); Kadcyla (trastuzumab emtamsine); MabThera/Rituxan (rituximab); Perjeta (pertuzumab); Tarceva (erlotinib); Xeloda (capecitabine); Zelboraf (vemurafenib). Furthermore the Group has a robust oncology pipeline focusing on new therapeutic targets and novel combination strategies.
In addition to Roche’s innovative portfolio of cancer medicines, Roche is constantly developing new diagnostic tests that will have a significant impact on disease management for cancer patients. Within Roche there are more than 350 pharma and diagnostics collaborations, far more than half of which are in the field of oncology. With a broad portfolio of tumor markers for prostate, colorectal, liver, ovarian, breast, stomach, pancreatic and lung cancer, as well as a range of tissue and molecular oncology tests that contribute to personalized cancer care today, Roche is leading a new era of innovation in the fight against cancer.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the WHO Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.